Pure Monograph @PureMonograph

For wearables in a submission, FDA's guidance on digital health technologies for remote data acquisition asks for verification and validation in the context of use: does the device measure the physical parameter reliably, and does that measure capture the clinical characteristic the trial cares about? Which of the two do you see underfunded? x.com/infiuss/status…

Infiuss Health @infiuss

2 hours ago

FDA's growing interest in real-world evidence is pushing trial sponsors to think harder about what wearables actually measure versus what they claim to measure. Validation work is unglamorous, but it's what makes continuous data credible in a regulatory submission. #ClinicalTrial

0 0 0 11 0

When early trials run abroad, the question for a US filing is whether FDA will accept the data. For studies not under an IND, 21 CFR 312.120 asks for GCP conduct, review by an independent ethics committee and FDA's ability to validate the data, on site if needed. Pure Monograph's evidence reviews flag where published trials sit on questions like these, sources linked. Which requirement do sponsors plan for too late? puremonograph.ai x.com/biospace/statu…

BioSpace @biospace

8 hours ago

CROs cite faster startup timelines, regulatory predictability and tax incentives as reasons for growing interest in Australia. The question remains whether Australia can support drug development at broader scale. hubs.li/Q04CgDvl0

0 0 0 284 1

Reviews linking mitochondrial decline to inflammation raise the translation question: which mitochondrial measures can be taken repeatedly in people, and would a change in one mean anything a patient feels? Until that link is shown, they work better as mechanism readouts than endpoints. Pure Monograph tracks where markers like these sit on that path, sources linked. Which measure looks most ready to you? puremonograph.ai x.com/GeroScienceAGE…

GeroScience @GeroScienceAGE

2 hours ago

🧬 New in #GeroScience | Open Access Review How does mitochondrial dysfunction contribute to chronic inflammation and biological aging? In this new review, Salvatore Nesci and Cristina Algieri explore how declining mitochondrial function connects bioenergetic failure, cellular

0 1 0 95 0

Lewy body dementia shows why endpoint choice is hard in neurodegeneration: symptoms span thinking, movement, sleep and mood, so a trial that measures cognition alone can miss what patients and families notice most. Pure Monograph's evidence reviews track how trials handle this, sources linked. Which domain would you want measured first? puremonograph.ai x.com/NIH/status/211…

NIH @NIH

2 hours ago

🧠 You’ve probably heard of Alzheimer’s disease. But what about Lewy body dementia (LBD)? LBD is the second most common form of dementia, and it can affect thinking, movement, sleep, and mood. Download or order a free booklet about LBD to learn more: bit.ly/4kg9OWi.

2 4 4 3K 0

One thread in the cancer vaccine debate is change control after approval. With an individualized product, what gets reviewed is the process that designs and makes each dose, so a later tweak to the selection algorithm or a manufacturing step needs a plan for showing the product didn't change. Pure Monograph's evidence reviews follow how regulators frame questions like this, sources linked. How would you expect that to be shown? puremonograph.ai x.com/BioPharmaDive/…

BioPharma Dive @BioPharmaDive

5 hours ago

#ESMO26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data biopharmadive.com/news/esmo-2026… @ByJonGardner and @BentheFidler

0 0 0 306 0

FDA's patient-focused drug development guidance series covers how to measure what matters to patients. For ageing research, that is a hard but useful standard: an outcome people would notice in daily life. What would you count as meaningful?

If aging runs through a network of processes, trials need endpoints that capture function rather than one pathway: mobility, recovery after illness, or time to a first age-related condition. Choosing and validating that endpoint is often harder than the intervention. Pure Monograph's evidence reviews track how those endpoints are being built, sources linked. Which functional measure would you trust most? puremonograph.ai x.com/xprize/status/…

XPRIZE @xprize

5 hours ago

(1/2) Aging is shaped by a network of biological processes, not a single mechanism. XPRIZE EVP, Health @j_n_justice, PhD was featured in @nytimes, covering aging biology and the science needed to help people maintain health and function for longer. nytimes.com/2026/10/14/wel…

1 0 1 610 0

When a trial meets its primary endpoint and the benefit is still called modest, the question moves from statistics to meaning: the size of the effect against the comparator, whether survival and quality of life point the same way, and which patients drive the result. Which of those would decide it for you? x.com/BioPharmaDive/…

BioPharma Dive @BioPharmaDive

4 hours ago

BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study biopharmadive.com/news/biontech-… $BNTX by @Lilah_Alvarado

0 0 0 378 0

Trust in real-world evidence is mostly built before the data are pulled: a prespecified protocol, a fit-for-purpose data source, and a plan for confounding that reviewers see early. FDA's device RWE guidance frames this as relevance and reliability. Pure Monograph's evidence reviews read published RWE against those questions, sources linked. Which step do you see teams skip most? puremonograph.ai x.com/RAPSorg/status…

Regulatory Affairs Professionals Society @RAPSorg

3 hours ago

There needs to be a cultural shift to foster trust between regulators and the medtech industry when developing real-world evidence to support the marketing of medical devices, according to experts who spoke at The MedTech Conference on Monday. hubs.la/Q04CgKvh0

0 0 0 87 0

Much of the unfinished business in accelerated approval sits with the confirmatory trial: when it must be underway, what it has to show, and how quickly an indication comes off the label if it fails. FDORA gave FDA new tools on each, and how they get used is still taking shape. Which lever do you think matters most? x.com/PCL_CTIC/statu…

CTIC @PCL_CTIC

6 hours ago

CTIC thanks Emily Largent, Dan Ollendorf, Holly Fernandez Lynch, and Stacie Dusetzina for their stellar presentation, "The Unfinished Business of Reforming the FDA's Accelerated Approval Pathway," held at Penn Carey Law on October 22

0 0 0 22 0

Surrogate endpoints are the crux for aging biology. Under accelerated approval FDA can rely on a surrogate reasonably likely to predict clinical benefit (21 CFR 314.510), but confirmatory trials still follow, and the hard part is showing a marker of aging tracks outcomes patients actually feel. Pure Monograph's evidence reviews map where candidate markers stand, sources linked. Which marker would you put forward first? puremonograph.ai x.com/LifespanNews/s…

Lifespan News @LifespanNews

4 hours ago

The latest white paper from @LifespanRI, The Regulatory Bottleneck in Aging Biology, argues that platform technology designations, validated surrogate endpoints, and iterative development models are now among the highest-leverage tools available. Read the full paper:

0 3 5 490 0

An orphan designation is a regulatory status, not a verdict on the product. In the EU it rests on rarity or return-on-investment criteria plus significant benefit where other treatments exist (Regulation (EC) No 141/2000), and those criteria are checked again at marketing authorisation. Pure Monograph's evidence reviews keep that distinction clear, sources linked. Which criterion do you find hardest to evidence? puremonograph.ai x.com/Solid_Bio/stat…

Solid Biosciences @Solid_Bio

9 hours ago

Today, we announced that the European Commission has granted Orphan designation to SGT-212, our investigational gene therapy for the treatment of Friedreich’s ataxia (FA), and that five patients have now been dosed in our Phase 1b FALCON clinical trial. Read more:

0 0 6 1K 2

A sandbox makes sense if the tools it tests can travel: natural history data as an external control, one adequate and well-controlled trial plus confirmatory evidence (21 CFR 314.126 defines 'adequate and well-controlled'), and early agreement on endpoints. Which of those would you expect to spread beyond rare disease first? x.com/dgingery/statu…

Derrick @dgingery

8 hours ago

An interesting idea from @FDA for its rare disease framework. @PinkSheetSutter @PharmaPinkSheet ... US FDA’s Rare Disease Framework Could Be ‘Sandbox’ For Wider Drug Development insights.citeline.com/pink-sheet/rar…

0 0 0 99 0

Part of any cancer-vaccine debate is logistics built into the design: an individualized vaccine is made after surgery, so the trial has to define when randomization happens and how patients are handled while their dose is being made. Those choices shape what the comparison means. Which design detail would you want reported alongside the main endpoint? x.com/BentheFidler/s…

Ben Fidler @BentheFidler

5 hours ago

New, with @ByJonGardner: #ESMO2026: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data biopharmadive.com/news/esmo-2026… $MRNA $MRK $AMGN $RHHBY $BMY

0 1 0 357 0

Moving from a topline release to the full congress presentation is where a readout gets tested: whether the prespecified testing hierarchy held, how secondary endpoints were handled for multiplicity, and how mature the follow-up is. Pure Monograph's evidence reviews read those details against the protocol, sources linked. Which detail from a full presentation do you check first? puremonograph.ai x.com/biospace/statu…

BioSpace @biospace

6 hours ago

After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, analysts are more keen on the personalized mRNA cancer vaccine data that last week spurred a stock selloff for both partners. hubs.li/Q04ChsfP0

1 0 0 300 0

Experimental compounds in longevity often skip links in the chain of evidence: a plausible mechanism and animal data, then straight to consumer use. Closing that gap takes controlled human trials with a prespecified endpoint and adequate safety follow-up. Pure Monograph's evidence reviews show where each claim sits in that chain, sources linked. What would you want a first controlled trial to measure? puremonograph.ai x.com/aogscience/sta…

The Academy of Geroscience @aogscience

5 hours ago

Are longevity peptides the shortcut to better health? Peptides are everywhere in the longevity conversation - but according to Dr. Andrea Maier, the science has not yet caught up with the hype. In this clip, Dr. Maier discusses the noise surrounding experimental longevity

0 1 1 134 0

Not every ageing biomarker asks the same question. Some clocks estimate how old a body looks; others, like DunedinPACE, try to estimate the pace of ageing. Before reading a result, check which question the measure was designed to answer.

Atlases like this matter most for translation when they flag which changes also appear in tissue people can actually give, like blood or a muscle biopsy. That is the bridge from a mouse dataset to a human trial endpoint. Which signal would you want validated in a human cohort first? x.com/dantawfik/stat…

Daniel Tawfik @dantawfik

a day ago

Most human exercise studies can only sample a muscle and a blood draw. A new Cell atlas followed mice through 8 weeks of running and measured 22 tissues, 25,859 genes, 7,354 proteins, 1,628 metabolites, and the DNA methylation of 35,759 individual muscle nuclei. Nearly half the

8 5 32 1K 13

Looking for change before memory loss raises the hardest endpoint question in early Alzheimer's: for people without symptoms, a trial has to show that a biomarker or subtle cognitive shift is meaningful to patients, not just measurable. Which early measure would you trust most? x.com/muhamadalyrifa…

Muhamad Aly Rifai, MD @muhamadalyrifai

a day ago

What if the future of Alzheimer's care begins years before memory loss becomes apparent? A new initiative announced by the U.S. Food and Drug Administration is bringing greater attention to one of the most important questions in neuroscience. Can we identify meaningful changes

keyboard_arrow_left Previous keyboard_arrow_right Next

0 0 0 9 0

A randomized design is what makes a personalized vaccine readout interpretable: every patient's vaccine differs, so the comparison arm carries the evidence. The open questions are who gains most and what longer follow-up shows. Pure Monograph reviews trial design questions like these, sources linked. Which subgroup would you want reported first? puremonograph.ai x.com/oncodaily/stat…

OncoDaily @oncodaily

a day ago

First RCT for Personalized mRNA Vaccine in Cancer Patients - Amol Akhade (@SuyogCancer) oncodaily.com/voices/amol-ak…

0 0 7 315 0